Collectively, these findings highlight FABP4 as a key driver of myometrial dysfunction in obesity and a potential therapeutic target for improving labor outcomes in obese pregnancies. This evidence concerns the gene FABP4 and obesity due to melanocortin 4 receptor deficiency.